Filing Details

Accession Number:
0001179022-18-000056
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-06-21 16:18:37
Reporting Period:
2018-06-19
Accepted Time:
2018-06-21 16:18:37
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1133416 Galectin Therapeutics Inc GALT Pharmaceutical Preparations (2834) 043562325
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1266773 W Jack Callicutt C/O Galectin Therapeutics, Inc.
4960 Peachtree Industrial Blvd., Ste 240
Norcross GA 30071
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-06-19 102,733 $4.41 103,993 No 4 M Direct
Common Stock Acquisiton 2018-06-19 26,000 $3.45 129,993 No 4 M Direct
Common Stock Disposition 2018-06-19 128,733 $9.01 1,260 No 4 S Direct
Common Stock Acquisiton 2018-06-20 97,267 $4.41 98,527 No 4 M Direct
Common Stock Disposition 2018-06-20 97,267 $8.08 1,260 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock option (right to buy) Disposition 2018-06-19 102,733 $0.00 102,733 $4.41
Common Stock Stock option (right to buy) Disposition 2018-06-19 26,000 $0.00 26,000 $3.45
Common Stock Stock option (right to buy) Disposition 2018-06-20 97,267 $0.00 97,267 $4.41
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
97,267 2023-07-01 No 4 M Direct
0 2025-01-29 No 4 M Direct
0 2023-07-01 No 4 M Direct
Footnotes
  1. The options vested as follows: (i) 12.5% on December 31, 2013, (ii) 25% on December 31, 2014, (iii) 25% on December 31, 2015, and (iv) 50% on December 31, 2016.
  2. The options vested as follows: 25% on January 29, 2016, the grant date, with the remainder vesting ratably on a monthly basis over a three year period.
  3. The shares were sold in multiple transactions at prices ranging from $9.00 to $9.0266. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  4. The shares were sold in multiple transactions at prices ranging from $8.0054 to $8.2592. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.